Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.70−0.05 (-6.48%)
Close on Nov 18, 2026Market cap $240.43MP/E –Yield 0.00%
Allogene Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Allogene Therapeutics's shares outstanding was 329M at Jun 30, 2026. For fiscal 2025 it was 221M, up 13.2% from the year before. The highest annual figure on record is 221M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 221M | +13.2% |
| FY2024 | Dec 31, 2024 | 195M | +24.1% |
| FY2023 | Dec 31, 2023 | 157M | +9.6% |
| FY2022 | Dec 31, 2022 | 143M | +5.4% |
| FY2021 | Dec 31, 2021 | 136M | +12.8% |
| FY2020 | Dec 31, 2020 | 120M | +19.1% |
| FY2019 | Dec 31, 2019 | 101M | +249.1% |
| FY2018 | Dec 31, 2018 | 29M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 329M | +50.2% |
| Q1 FY2026 | Mar 31, 2026 | 240M | +11.6% |
| Q4 FY2025 | Dec 31, 2025 | 226M | +7.3% |
| Q3 FY2025 | Sep 30, 2025 | 222M | +6.1% |
| Q2 FY2025 | Jun 30, 2025 | 219M | +15.2% |
| Q1 FY2025 | Mar 31, 2025 | 215M | +27.3% |
| Q4 FY2024 | Dec 31, 2024 | 211M | +25.1% |
| Q3 FY2024 | Sep 30, 2024 | 209M | +24.8% |
| Q2 FY2024 | Jun 30, 2024 | 190M | +29.4% |
| Q1 FY2024 | Mar 31, 2024 | 169M | +17.0% |
| Q4 FY2023 | Dec 31, 2023 | 168M | +16.9% |
| Q3 FY2023 | Sep 30, 2023 | 168M | +16.7% |
| Q2 FY2023 | Jun 30, 2023 | 147M | +2.4% |
| Q1 FY2023 | Mar 31, 2023 | 145M | +2.3% |
| Q4 FY2022 | Dec 31, 2022 | 144M | +3.6% |
| Q3 FY2022 | Sep 30, 2022 | 144M | +4.8% |
| Q2 FY2022 | Jun 30, 2022 | 143M | +6.3% |
| Q1 FY2022 | Mar 31, 2022 | 141M | +7.0% |
| Q4 FY2021 | Dec 31, 2021 | 139M | +7.3% |
| Q3 FY2021 | Sep 30, 2021 | 137M | +7.8% |
| Q2 FY2021 | Jun 30, 2021 | 135M | +16.9% |
| Q1 FY2021 | Mar 31, 2021 | 132M | +21.3% |
| Q4 FY2020 | Dec 31, 2020 | 130M | +23.8% |
| Q3 FY2020 | Sep 30, 2020 | 127M | +24.4% |
| Q2 FY2020 | Jun 30, 2020 | 115M | +15.6% |
| Q1 FY2020 | Mar 31, 2020 | 109M | +12.0% |
| Q4 FY2019 | Dec 31, 2019 | 105M | +2482.0% |
| Q3 FY2019 | Sep 30, 2019 | 102M | +3219.1% |
| Q2 FY2019 | Jun 30, 2019 | 100M | +280.4% |
| Q1 FY2019 | Mar 31, 2019 | 97M | – |
| Q3 FY2018 | Sep 30, 2018 | 4M | – |
| Q2 FY2018 | Jun 30, 2018 | 3M | – |
| Q1 FY2018 | Mar 31, 2018 | 26M | – |
See a number that looks wrong?